This model is relevant to human health, as Trp2 is a common target in cancer immunotherapy directed against melanoma (Cho and Celis, 2009; Liu et al., 2014; Parkhurst et al., 1998), and Trp2/Kb-specific responses can be induced in WT mice with vigorous priming approaches (Bowne et al., 1999; Byrne et al., 2011; Cho and Celis, 2009). This evidence concerns the gene DCT and melanoma.